ArtivaBio
@artivabio
We are dedicated to making safe and effective cell therapies accessible to any cancer patient who may benefit. #NKcelltherapy #celltherapy #cancer #NKcells
ID: 1268370181882933248
http://www.artivabio.com 04-06-2020 02:33:56
91 Tweet
335 Followers
44 Following
Natural killer (NK) cells are redefining the field of cell therapies. Learn how Artiva's #AlloNK has the potential to provide scalable, cost-effective, safe, and efficacious allogeneic therapies for #autoimmunedisease. š Read more in PharmaVoice: pharmavoice.com/news/natural-kā¦
We are excited to welcome to our Board of Directors, Dr. Dan Baker, a seasoned leader in clinical development and regulatory strategy, including leading programs for RemicadeĀ®, SimponiĀ®, and StelaraĀ®. Read more here: investors.artivabio.com/News-and-Eventā¦ $ARTV #AutoimmuneDisease #AlloNK
.In Vivo, Citeline Commercial highlights how Artiva is leveraging our #AlloNK platform to challenge the CAR-T paradigm. @DavidWild77 shares how our approach to #NKcells could make cell therapy more accessible to patients with #autoimmunedisease. insights.citeline.com/in-vivo/innovaā¦
Artiva will be presenting at the šš¬ššµ šš»š»šš®š¹ šš»š»š®šš² šš¶š¹š¹š²šæ š¦ššŗšŗš¶š taking place March 3-5 in San Diego, covering the latest in NK cells in #autoimmunedisease, scalable manufacturing, and clinical advancements. See more: innate-killer.com #AlloNK
Artiva will present at the TD Cowen 45th Annual Health Care Conference on March 5 at 2:30 p.m. EST in Boston. Join us for insights into the latest advancements in NK #celltherapy for #autoimmunediseases. Webcast and more info here: investors.artivabio.com/News-and-Eventā¦ $ARTV #NKcells #lupus
How is Artiva pairing š½šæš²š°š¶šš¶š¼š» & š½š¼šš²šæ to transform #autoimmune treatment? CEO Fred Aslan talks to š§šµš² šš¶š¼ š„š²š½š¼šæš's Daniel S. Levine about using proven mAbs to target cells & deliver a cytotoxic AlloNKĀ® cell payload. šļøListen now: bit.ly/3R2YPQf
How can #NKcells transform autoimmune treatment? Artivaās CEO shares insights on our dual clinical trial strategy, FDA Fast Track, and how AlloNKĀ® can provide an immune rest for serious #autoimmunediseases. Watch the first Pharmaceutical Executive interview here: pharmexec.com/view/artiva-auā¦
Artiva has named Dr. Subhashis Banerjee as Chief Medical Officer. He has contributed to the development of multiple approved therapies, such as HumiraĀ®, TaltzĀ®, OrenciaĀ®, and SotyktuĀ® and joins as we advance AlloNKĀ® in B-cell driven autoimmune diseases. investors.artivabio.com/News-and-Eventā¦
Congrats to Neha Krishnamohan, CFO & EVP at Artiva, on being named one of In Vivoās 2025 Rising Leaders! Sheās led key milestones, including a successful IPO, to advance our mission to deliver NK cell therapies for autoimmune diseases and cancer. insights.citeline.com/in-vivo/leaderā¦
What's an 'immune reset' and how is Artiva making the most of mAbs to achieve it? Artiva CEO Fred Aslan spoke to Genetic Engineering & Biotechnology News about how combining off-the-shelf AlloNKĀ® cells with monoclonal antibodies can deplete the B-cells that cause #autoimmune conditions. genengnews.com/topics/cancer/ā¦
Artiva will participate in a fireside chat and 1x1 meetings at the Jefferies 2025 Global Healthcare Conference. Join us for insights into the latest on #AlloNK for the treatment of autoimmune diseases. Press release: investors.artivabio.com/News-and-Eventā¦ $ARTV #AlloNK #JefferiesHealthcare
NK cells = a new frontier for autoimmune disease treatment. In this recent Q&A, Artiva CEO Fred Aslan, M.D., discusses how AlloNKĀ® can potentially deliver deep B-cell depletion, an improved safety profile, and off-the-shelf scalability for broader access. pharmaceuticalmanufacturer.media/pharmaceuticalā¦
Artiva CMO Dr. Subhashis Banerjee speaks with Inside Precision Medicine about our integrated #clinicaltrial strategy to evaluate #AlloNK across #autoimmunediseases, identifying shared disease mechanisms and guiding future development. Read the Q&A here: insideprecisionmedicine.com/topics/precisiā¦